• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Teva Pharmaceutical Industries ADR (NY: TEVA )

    18.38 -0.21 (-1.13%)
    Streaming Delayed Price Updated: 1:22 PM EDT, Oct 31, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Teva Pharmaceutical Industries ADR

    < Previous 1 2 3 4 5 6 7 Next >
    Teva Statement on European Commission Decision; Company to Appeal
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate
    From Teva Pharmaceutical Industries Ltd; mAbxience
    Via GlobeNewswire
    Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S.
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    Teva to Host Conference Call to Discuss Third Quarter 2024 Financial Results at 8 a.m. ET on November 6, 2024
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
    EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:NTRBW),(NYSE:TEVA),(NYSE:LLY),(NYSE:NVS),(NASDAQ:AMRX) EQNX::TICKER_END 
    Via FinancialNewsMedia
    Exposures Product Safety
    As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
    From FN Media Group LLC
    Via GlobeNewswire
    Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive Dyskinesia
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000)
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    Teva to Present at the Bank of America 2024 Global Healthcare Conference
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    Teva to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    Revolutionary Magnetic Therapy Could Speed Up Bipolar Treatment
    New research suggests that powerful magnets could effectively treat bipolar disorder. This therapy, which is known as accelerated intermittent theta burst stimulation (iTBS), uses magnetic waves... 
    Via PressReach
    Exposures Product Safety
    Teva Announces Strong Growth in Second Quarter Revenues mainly driven by Generics Products in All Regions and AUSTEDO®; Raises 2024 Financial Guidance
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    Teva and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inflammatory Bowel Disease
    From Teva Pharmaceutical Industries Limited
    Via Business Wire
    Teva Announces First Phase 3 Evidence of Efficacy and Safety of an Anti-CGRP Monoclonal Antibody in Children in AJOVY® (fremanezumab) SPACE Trial for Prevention of Episodic Migraine
    From Teva Pharmaceutical Industries Limited
    Via Business Wire
    Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem
    Drug prices continue to rise, driving up healthcare costs. Pharmaceutical companies usually hike drug prices at the beginning of each year. In January 2024 
    Via MarketBeat
    Teva to Host Conference Call to Discuss Second Quarter 2024 Financial Results at 8 a.m. ET on July 31, 2024
    From Teva Pharmaceutical Industries Limited
    Via Business Wire
    New AJOVY® (fremanezumab) Migraine Prevention Data Challenges Treatment Pauses
    From Teva Pharmaceutical Industries Limited
    Via Business Wire
    Teva Reaches Agreement With the Israel Tax Authority to Resolve All Pending Litigation for the Company's Taxable Years 2008-2020
    From Teva Pharmaceutical Industries Limited
    Via Business Wire
    Teva Announces Launch of Authorized Generic of Victoza® (liraglutide injection 1.8mg), in the United States
    From Teva Pharmaceutical Industries Limited
    Via Business Wire
    What is a Bull Flag Pattern? Explanation and Examples
    Learn how to identify and trade the bull flag pattern, which is a key tool for spotting continuations in bullish trends. 
    Via MarketBeat
    Teva to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
    From Teva Pharmaceutical Industries Limited
    Via Business Wire
    New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)
    From Teva Pharmaceutical Industries Limited
    Via Business Wire
    Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024
    From Teva Pharmaceutical Industries Limited
    Via Business Wire
    2 Generic Drug Makers With Growing Runways
    Brand name drug costs continue to climb but patients and insurers find respite by migrating to generic or biosimilar versions as patents run out. 
    Via MarketBeat
    Topics Intellectual Property
    Exposures Intellectual Property
    Teva Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 mg/day)
    From Teva Pharmaceutical Industries Limited
    Via Business Wire
    Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
    From Teva Pharmaceutical Industries Limited
    Via Business Wire
    Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
    From Alvotech
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.